Open AccessRepeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case
Author(s) -
Santoro Cristina,
Volpicelli Paola,
Baldacci Erminia,
Ferrara Grazia,
Di Rocco Alice,
Ferretti Antonietta,
Porrazzo Marika,
Mazzucconi Maria Gabriella
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.920
Subject(s) - eltrombopag , medicine , thrombopoietin , immune thrombocytopenia , romiplostim , thrombopoietin receptor , platelet , immunology , haematopoiesis , genetics , stem cell , biology
Key Clinical Message Thrombopoietin receptor agonists ( TPO ‐ RA s) are used as effective alternative treatments in ITP patients unresponsive to first‐/second‐line therapies. TPO ‐ RA s can also be used to normalize platelet count to safely perform invasive procedures and chemotherapy, in case of malignancies. In few responsive patients, TPO ‐ RA s can be suspended maintaining a sustained response.